OTCMKTS:EPRXF Eupraxia Pharmaceuticals (EPRXF) Stock Price, News & Analysis → Democrats Push to Replace Dollar With Digital Coin, Control Currency. (From Monetary Gold) (Ad) Free EPRXF Stock Alerts C$2.95 -0.03 (-1.01%) (As of 05/16/2024 ET) Add Compare Share Share Today's RangeC$2.95▼C$2.9850-Day RangeC$2.51▼C$5.0152-Week RangeC$2.93▼C$6.78Volume16,303 shsAverage Volume7,410 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetC$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Eupraxia Pharmaceuticals alerts: Email Address Ad Monetary GoldDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. About Eupraxia Pharmaceuticals Stock (OTCMKTS:EPRXF)Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.Read More EPRXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EPRXF Stock News HeadlinesMay 8, 2024 | americanbankingnews.comEupraxia Pharmaceuticals (OTCMKTS:EPRXF) Trading 2.1% Higher April 27, 2024 | markets.businessinsider.comEQS-News: CHEPLAPHARM closes financial year 2023 with record revenue and double-digit growthApril 20, 2024 | ca.finance.yahoo.comEupraxia Pharmaceuticals Inc (EPRX-WT.TO)April 11, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024April 11, 2024 | prnewswire.comEupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024April 3, 2024 | finance.yahoo.comEupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024April 1, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsMarch 29, 2024 | markets.businessinsider.comEQS-News: APONTIS PHARMA expects profitable growth again in 2024March 15, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 MillionMarch 12, 2024 | marketwatch.comEupraxia Pharma Shares Drop After Stock Offering PricesMarch 12, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - EPRXMarch 12, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 MillionMarch 11, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 MillionMarch 1, 2024 | seekingalpha.comProfit Setback For Simcere Pharma In Novel Drugs QuestFebruary 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Morphic Holding (MORF) and Vertex Pharmaceuticals (VRTX)February 15, 2024 | msn.comWest Pharmaceutical reports mixed Q4 results; initiates FY24 outlookFebruary 15, 2024 | reuters.comMedical equipment maker West Pharmaceutical forecasts weak annual resultsFebruary 6, 2024 | marketwatch.comVertex Pharmaceuticals 4Q Net, Revenue Beat EstimatesFebruary 5, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic EsophagitisFebruary 1, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IARJanuary 30, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the KneeJanuary 8, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf ProspectusJanuary 1, 2024 | seekingalpha.comLexicon Pharmaceuticals: Navigating The Competitive HFpEF Landscape (Rating Downgrade)December 16, 2023 | morningstar.comEupraxia Pharmaceuticals Inc Ordinary Shares EPRXDecember 13, 2023 | marketwatch.comEditas Medicine Strikes License Deal With Vertex Pharmaceuticals -- UpdateSee More Headlines Receive EPRXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:EPRXF CUSIPN/A CIKN/A Webwww.eupraxiapharma.com Phone250 590 3968FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Stock Price TargetC$18.00 High Stock Price TargetC$18.00 Low Stock Price TargetC$18.00 Potential Upside/Downside+510.2%Consensus RatingStrong Buy Rating Score (0-4)4.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. James A. Helliwell FRCPC (Age 50)M.D., CEO & Director Comp: $463.72kMr. Bruce G. Cousins C.A. (Age 63)CPA, President & CFO Comp: $311.61kDr. Amanda Malone Ph.D. (Age 43)Chief Scientific Officer Comp: $343.63kMr. Paul Anthony Brennan B.Sc.M.Sc., Chief Business OfficerDr. Mark M. Kowalski M.D. (Age 69)Ph.D., Chief Medical Officer Key Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors EPRXF Stock Analysis - Frequently Asked Questions Should I buy or sell Eupraxia Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eupraxia Pharmaceuticals in the last twelve months. There are currently 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "strong buy" EPRXF shares. View EPRXF analyst ratings or view top-rated stocks. What is Eupraxia Pharmaceuticals' stock price target for 2024? 1 brokerages have issued 12-month price targets for Eupraxia Pharmaceuticals' stock. Their EPRXF share price targets range from C$18.00 to C$18.00. On average, they anticipate the company's share price to reach C$18.00 in the next year. This suggests a possible upside of 510.2% from the stock's current price. View analysts price targets for EPRXF or view top-rated stocks among Wall Street analysts. How have EPRXF shares performed in 2024? Eupraxia Pharmaceuticals' stock was trading at C$4.16 at the beginning of the year. Since then, EPRXF shares have decreased by 29.1% and is now trading at C$2.95. View the best growth stocks for 2024 here. How do I buy shares of Eupraxia Pharmaceuticals? Shares of EPRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:EPRXF) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyDems have chosen Biden replacement?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldProtect Your Bank Account Before It’s Too LateWeiss Ratings348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
